PRME
Prime Medicine, Inc.
NASDAQ · Healthcare · Biotechnology · US
$3.70
−0.27%Year over year
Reported trailing growth
- Revenue
- -17.9%
- EBITDA
- +8.0%
- EBIT
- +3.8%
- EPS
- +31.2%
- Free cash flow
- -46.6%
- Operating cash flow
- -56.2%
Forward estimates
Based on analyst estimates
- Revenue
- +143.8%
- EBITDA
- +9.2%
- EPS
- +12.4%
Three-year CAGR
- Revenue
- +55.3%
- EBITDA
- -3.2%
- EBIT
- -2.9%
- Net income
- -2.7%
- EPS
- +18.3%
- Free cash flow
- -28.4%
Reported trailing growth, forward expectations and three-year compound growth rates · Data as of Jun 1, 2026